Cellectis (NASDAQ:CLLS) Stock Price Crosses Below Fifty Day Moving Average – Time to Sell?

Shares of Cellectis S.A. (NASDAQ:CLLS) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.67 and traded as low as $3.10. Cellectis shares last traded at $3.11, with a volume of 9,983 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CLLS. Citizens Jmp reiterated a “market outperform” rating and set a $8.00 price target on shares of Cellectis in a research report on Tuesday, April 14th. Barclays began coverage on Cellectis in a research report on Thursday, May 28th. They set an “overweight” rating and a $9.00 price target for the company. Jefferies Financial Group initiated coverage on Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Cellectis Price Performance

The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $312.06 million, a PE ratio of -4.64 and a beta of 2.86. The company has a 50-day moving average of $3.67 and a 200 day moving average of $3.94.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million.

Hedge Funds Weigh In On Cellectis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLLS. Lido Advisors LLC acquired a new position in Cellectis during the first quarter worth $32,000. Global Retirement Partners LLC acquired a new position in Cellectis during the fourth quarter worth $34,000. Acadian Asset Management LLC boosted its stake in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares during the last quarter. Delaney Dennis R acquired a new position in Cellectis during the third quarter worth $68,000. Finally, Virtu Financial LLC acquired a new position in Cellectis during the third quarter worth $72,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.